Development of a Hypoallergenic Recombinant Parvalbumin for First-in-Man Subcutaneous Immunotherapy of Fish Allergy

2015106 citationsJournal Articlebronze Open Access

Authors

Laurian Zuidmeer · Amsterdam UMC Location University of Amsterdam

H. Huber · Biomay (Austria)

Ines Swoboda · Medical University of Vienna

Neil M. Rigby · Norwich Research Park

Serge A. Versteeg · Amsterdam UMC Location University of Amsterdam

Bettina M. Jensen · Gentofte Hospital

Suzanne Quaak

Abstract

The GMP drug product developed for treatment of fish allergy has the characteristics targeted for in FAST: i.e. hypoallergenicity with retained immunogenicity. These results have warranted first-in-man immunotherapy studies to evaluate the safety of this innovative vaccine.

Topics & Keywords

Allergic Rhinitis and Sensitization Food Allergy and Anaphylaxis Research Asthma and respiratory diseases

Publication Details

Published in: International Archives of Allergy and Immunology

Volume 166, Issue 1, pp. 41-51

DOI: 10.1159/000371657

Field-Weighted Citation Impact: 7.72

Command Palette

Development of a Hypoallergenic Recombinant Parvalbumin for First-in-Man Subcutaneous Immunotherapy of Fish Allergy

Authors

Abstract

Topics & Keywords

Publication Details